Observational studyLasers in medical science2026
Narrowband ultraviolet B phototherapy for dermatoses seen in elderly: a real-life experience.
Observational study in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite therapeutic advances such as biologics and small-molecule inhibitors, narrowband ultraviolet B (NB-UVB) phototherapy remains essential in dermatology. In recent years, the elderly population has been increasing worldwide, so NB-UVB will be more crucial in geriatric dermatology. In this study, we aimed to evaluate the efficacy and safety of NB-UVB in various dermatoses seen in elderly patients. This observational, retrospective study included patients over 65 who received NB-UVB for any dermatological disease between 2014 and 2024. We retrospectively reviewed the phototherapy and clinical follow-up forms of the patients. A total of 126 patients were included in this study. Fifty-two (41.3%) patients were male and 74 (58.7%) were female. The mean age of the patients was 71.9 ± 6.90 years. NB-UVB was administered most frequently to 30 (23.8%) of the patients with the diagnosis of generalized pruritus, 23 (18.3%) with mycosis fungoides, 20 (15.9%) with psoriasis, 15 (11.9%) with lichen planus, and 14 (11.1%) with prurigo nodularis. The mean number of sessions was 47.7 ± 21.4, and the cumulative UVB dose was 73.17 ± 49.87 J/cm2 in all patients. 68 (%54) patients achieved complete response, and 46 (%36.5) patients achieved partial response. Mild side effects were observed in 23 (18.3%) patients. None of them led to discontinuation of treatment. Antinuclear antibody (ANA) was positive in 29.4% of the patients. There was no statistically significant difference between ANA positivity and side effect development (p = 0.644). NB-UVB is an effective and safe treatment option for dermatoses such as generalized pruritus, mycosis fungoides, psoriasis, lichen planus, prurigo nodularis in the elderly population,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.